Vision Capital Management Inc. Purchases Shares of 2,248 Danaher Corporation (NYSE:DHR)

Vision Capital Management Inc. bought a new position in Danaher Corporation (NYSE:DHR - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,248 shares of the conglomerate's stock, valued at approximately $461,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Telos Capital Management Inc. raised its stake in Danaher by 0.6% during the first quarter. Telos Capital Management Inc. now owns 45,281 shares of the conglomerate's stock valued at $9,283,000 after buying an additional 250 shares in the last quarter. Capital Insight Partners LLC raised its stake in Danaher by 6.2% during the first quarter. Capital Insight Partners LLC now owns 3,698 shares of the conglomerate's stock valued at $758,000 after buying an additional 216 shares in the last quarter. First Interstate Bank raised its stake in Danaher by 2.4% during the first quarter. First Interstate Bank now owns 3,533 shares of the conglomerate's stock valued at $724,000 after buying an additional 82 shares in the last quarter. Banque Pictet & Cie SA raised its stake in Danaher by 181.9% during the first quarter. Banque Pictet & Cie SA now owns 54,644 shares of the conglomerate's stock valued at $11,202,000 after buying an additional 35,262 shares in the last quarter. Finally, Axxcess Wealth Management LLC raised its stake in Danaher by 8.6% during the first quarter. Axxcess Wealth Management LLC now owns 12,924 shares of the conglomerate's stock valued at $2,649,000 after buying an additional 1,023 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares in the company, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Danaher Stock Down 0.3%

NYSE DHR traded down $0.71 during trading on Friday, hitting $204.80. 2,369,010 shares of the company traded hands, compared to its average volume of 3,508,130. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70. The business has a fifty day simple moving average of $196.05 and a 200 day simple moving average of $206.47. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $146.57 billion, a P/E ratio of 39.77, a PEG ratio of 2.89 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's dividend payout ratio is currently 24.85%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Bank of America cut their price objective on Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Barclays reiterated an "overweight" rating and set a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Leerink Partners increased their price target on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Finally, TD Cowen increased their price target on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $248.43.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.